U.S. EPA Approves New VectoPrime™ Biological Larvicide for Single-brood Floodwater Mosquito Larvae Programs


Breakthrough dual-action larvicide provides effective control in all four instar stages for all mosquito species

LIBERTYVILLE, IL, February, 24, 2015 – Valent BioSciences Corporation (VBC) announced that the U.S. Environmental Protection Agency (EPA) has granted registration approval for VectoPrimeTM Biological Larvicide for single-brood mosquito control. Through the power of BioFuseTM technology, VectoPrime is formulated with a specific ratio of Bacillus thuringiensis spp. israelensis Strain AM65-52 and (S)- methoprene developed through years of painstaking research. The result is a unique combination of efficacy, flexibility, and efficiency benefits to support U.S.-based mosquito abatement professionals.

The dual action of VectoPrime provides control from pre-hatch applications all the way through the 4th instar while delivering a host of related benefits. Asynchronous broods pose a significant challenge in the ongoing battle against mosquitos capable of transmitting harmful diseases such as West Nile virus, dengue fever, malaria, and encephalitis.

“The advanced technology and extended application window offered by VectoPrime allows Mosquito Abatement Districts to plan more and react less,” said Steve Krause, VBC’s Global Business Manager for Public Health and Forestry. “VectoPrime provides Districts the opportunity to streamline their process through lower application rates, which in turn translate into enhanced inventory management, greater agility, and greater value for mosquito control programs at the ground level.”

BioFuse is VBC’s patented formulation technology that combines precise amounts of two active ingredients within the space of a single microparticle. With VectoPrime, both active ingredients are released instantly upon contact with water to provide applicators with immediate, visible proof that mosquito larvae are dead. The product’s reduced application rates drive further operational efficiencies that result in savings on fuel, maintenance, and labor.

VectoPrimeTM joins VBC’s biorational mosquito larvicides VectoBac®, VectoMax®, MetaLarv®, VectoLex®, and Teknar® to provide the public health industry’s most comprehensive range of target-specific, biorational larvicides for mosquito abatement professionals and health care officials around the globe.

For more information about VectoPrimeTM or any other target-specific, biorational mosquito larvicides, visit http://publichealth.valentbiosciences.com/products/vectoprime


About Valent BioSciences Corporation
Headquartered in Libertyville, IL, Valent BioSciences is a subsidiary of Tokyo-based Sumitomo Chemical Company and is the worldwide leader in the development, manufacturing and commercialization of biorational products with sales in 95 countries around the world. Valent BioSciences is an ISO 9001:2008 Certified Company. For additional information, visit the company’s website at www.valentbiosciences.com

Media Contact:
Rick Melnick
Valent BioSciences Corporation
Email: rick.melnick@valentbiosciences.com


Related News

Valent BioSciences LLC announces its acquisition of FBSciences Holdings, Inc., a leader in the discovery and commercialization of naturally derived plant, soil, and climate health solutions.
The new solar field at Valent BioSciences’ manufacturing facility in Osage, Iowa, is now fully operational.
Valent BioSciences LLC, the global biorational products leader in agriculture, public health, and forest health, has announced that the company began selling biostimulant products directly to its U.S. customer base on October 1.
Sumitomo Chemical Co., Ltd. (SCC), parent company of Valent U.S.A. and Valent Biosciences, today announced a new entity called Valent North America that will provide enterprise business services across the Valent group of companies. 
Valent BioSciences LLC, the global biorational products leader in agriculture, public health, and forestry, has announced the promotion of Salman Mir to Executive Vice President and Chief Operating Officer. He will continue reporting to Ted Melnik, Valent BioSciences’ President and Chief Executive Officer.
To promote its industry leadership in biorational and biostimulant product innovation, Valent BioSciences LLC has announced significant investments at several of its key research and development facilities.